['We aimed to determine the impact of inosine triphosphatase (ITPA) deficiency on ribavirin (RBV) induced anemia in HIV-HCV co-infected patients receiving a triple therapy including the hematotoxic direct-acting antiviral agent boceprevir (BOC).', 'Patients of the ANRS HC27 BocepreVIH study were genotyped for 2 ITPA Single nucleotide polymorphisms involved in ITPA deficiency. RBV trough concentration (C', 'Among the 63 genotyped patients, 33% had a predicted ITPA deficiency. ITPA deficiency was associated with a lower hemoglobin (Hb) decline both at W4 (-1.0 g/dL vs -2.1 g/dL, p=0.02) and W8 (-2.7 g/dL vs -4.1 g/dL, p=0.05). None of the patients with ITPA deficiency received EPO between D0-W8 versus 26% of patients without ITPA deficiency (p=0.01). RBV C'] Are iTPA deficiency and ribavirin level still predictive of anaemia in HCV-HIV-coinfected patients receiving ribavirin combined with a first-generation DAA ( ANRS HC27 study )?